Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MSZBZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BB-1709
|
|||||
| Synonyms |
BB-1709
Click to Show/Hide
|
|||||
| Organization |
Bliss Biopharmaceutical (BlissBio) (Originator);Morphotek
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
|
|
||||||
| Antibody Name |
Anti-CD73 antibody
|
Antibody Info | ||||
| Antigen Name |
Thymidylate 5'-phosphatase (NT5E)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic solid tumors (RECIST 1.1 measurable), ECOG 0-1, and life expectancy ≥12 weeks. Key exclusions include recent anti-cancer therapies (within 2-4 weeks depending on type), active CNS metastases, grade ≥2 neuropathy, uncontrolled infections (HIV/HBV/HCV), pregnancy, or hypersensitivity to BB-1709 components.
Click to Show/Hide
|
||||
| Administration Dosage |
BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06241898 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1709 in Patients With Locally Advanced/Metastatic Solid Tumors | ||||
| Primary Endpoint |
The primary safety evaluation focuses on adverse events (AEs) and serious adverse events (SAEs) occurring within 3 years to assess BB-1709's safety profile.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes area under the serum concentration-time curve (AUC0-inf) measured during Cycles 1-8 (21-day cycles) to characterize BB-1709's exposure.
|
||||
References